Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Formoterol hydrofluoroalkane inhalation - Chiesi

Drug Profile

Formoterol hydrofluoroalkane inhalation - Chiesi

Alternative Names: Atimos; CHF 1531; eformoterol; Eformoterol HFA inhalation - Chiesi; Forair; formoterol fumarate; Formoterol HFA inhalation - Chiesi; Formoterol HFA Modulite; Formoterol Modulite

Latest Information Update: 23 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Jul 2018 Chiesi Farmaceutici completes the phase II FLASH trial in Asthma in USA (Inhalation) (NCT03086460)
  • 05 Dec 2017 Phase II development is ongoing in USA for Asthma
  • 08 Sep 2017 Chiesi Farmaceutici initiates enrolment in the phase II FLASH trial in Asthma in USA (Inhalation) (NCT03086460)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top